A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions

Healthy

Interventions

DRUG

Ixekizumab

Administered by SQ injection

DRUG

Boostrix®

Administered by IM injection

DRUG

Pneumovax®23

Administered by IM injection

Trial Locations (3)

Covance, Daytona Beach

Covance, Evansville

Covance, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02543918 - A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants | Biotech Hunter | Biotech Hunter